Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: A systematic literature review

Authors: Marc Evans, Susanne Engberg, Mads Faurby, João Diogo Da Rocha Fernandes, Pollyanna Hudson, William Polonsky

Abstract

We designed a systematic literature review to identify available evidence on adherence to and persistence with antidiabetic medication in people with type 2 diabetes (T2D). Electronic screening and congress searches identified real-world noninterventional studies (published between 2010 and October 2020) reporting estimates of adherence to and persistence with antidiabetic medication in adults with T2D, and associations with glycaemic control, microvascular and/or macrovascular complications, hospitalizations and healthcare costs. Ninety-two relevant studies were identified, the majority of which were retrospective and reported US data. The proportions of patients considered adherent (median [range] 51.2% [9.4%-84.3%]) or persistent (median [range] 47.7% [16.9%-94.0%]) varied widely across studies. Multiple studies reported an association between greater adherence/persistence and greater reductions in glycated haemoglobin levels. Better adherence/persistence was associated with fewer microvascular and/or macrovascular outcomes, although there was little consistency across studies in terms of which outcomes were improved. More adherent and more persistent patients were typically less likely to be hospitalized or to have emergency department visits/admissions and spent fewer days in hospital annually than less adherent/persistent patients. Greater adherence and persistence were generally associated with lower hospitalization costs, higher pharmacy costs and lower or budget-neutral total healthcare costs compared with lower adherence/persistence. In conclusion, better adherence and persistence in people with T2D is associated with lower rates of microvascular and/or macrovascular outcomes and inpatient hospitalization, and lower or budget-neutral total healthcare expenditure. Education and treatment strategies to address suboptimal adherence and persistence are needed to improve clinical and economic outcomes.

Source: https://pubmed.ncbi.nlm.nih.gov/34779107/

Share the Post:

BDI Monthly Events

November 11
November 11Case Consultation
November 11: BDI hosts the San Diego-wide, monthly case consultation meeting (for mental health professionals working in the field of diabetes). Contact us at info@behavioraldiabetes.org if you are in the greater San Diego area and would like further information about this program.
November 14
November 14World Diabetes Day!
November 14: World Diabetes Day! Time for another T1D meet-up! GrownupT1Ds, a wonderful nonprofit that organizes fun social events for adults with type 1 diabetes here in southern California and now spreading to other cities across the United States. The next local one will be at Brewery X, 3191 E. La Palma Ave., Anaheim, CA 92806. Things get started at 2:00 P.M. Please RSVP at kelly@grownup.t1ds.org
November 26
November 26Happy Thanksgiving!
This Thanksgiving, we are especially grateful for the individuals, families, healthcare professionals, and friends who make up the BDI community. Thank you for your continued support and for sharing in our mission to improve the emotional well-being of people living with diabetes. Wishing you and your loved ones a warm and happy Thanksgiving!
November 3
November 3Engaging the Disengaged
November 3: Dr. Polonsky (BDI President) will be speaking on “Engaging the Disengaged: Diabetes Distress, Diabetes Burnout and More” at the Southern California Permanente Medical Group’s 32th Annual Diabetes Hybrid Symposium, in Long Beach (CA).